Bristol Myers Squibb's FDA nod for Breyanzi (liso-cel) in relapsed/refractory CLL/SLL boosts its CAR T-cell portfolio, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback